



Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?

Wen Shi Lee^a and Stephen J. Kent^{a,b,c}

Purpose of review

An increasing body of evidence suggests that nonneutralizing Fc effector functions including antibody-dependent cellular cytotoxicity (ADCC) contribute to protection against HIV-1 acquisition. We discuss recent advances in anti-HIV-1 ADCC research with a particular focus on ADCC mediated by Env-specific antibodies *in vitro* and *in vivo*, the curative potential of HIV-1-specific ADCC antibodies and the mechanisms of HIV-1 resistance to ADCC.

Recent findings

ADCC activities of broadly neutralizing and nonneutralizing monoclonal antibody panels were recently characterized *in vitro* against several lab-adapted and primary isolates of HIV-1. ADCC activity of these monoclonal antibodies generally correlated with binding to infected cells and were greater against the lab-adapted strains compared with primary HIV-1 isolates. Several recent studies in mouse and macaque models of HIV-1 infection suggest Fc-mediated effector functions contribute to the protective efficacy of broadly neutralizing antibodies and exert immune pressure on HIV-1 *in vivo*.

Summary

An increasing body of evidence suggests that ADCC-mediating antibodies, particularly when combined with neutralizing functions, can facilitate prevention and control of HIV-1. The precise mechanisms of partial protection conferred by nonneutralizing antibodies *in vivo* remain unclear and will need to be fully investigated in order to realize their full potential for HIV-1 vaccines.

Keywords

antibody-dependent cellular cytotoxicity, broadly neutralizing antibody Fc-mediated effector functions, nonneutralizing

INTRODUCTION

Research on humoral immunity to HIV-1 has largely focused on generating broadly neutralizing antibodies (bNAbs), which can recognize a diverse range of HIV-1 strains and block infection through binding to crucial 'sites of vulnerability' on the HIV-1 Env trimer [1,2]. Passive transfer of bNAbs can reliably protect macaques from chimeric simian–human immunodeficiency virus (SHIV) challenge and humanized mice from challenges with HIV-1 [3–10]. The induction of bNAbs is considered the 'holy grail' of HIV-1 vaccine research but has proven difficult to achieve by vaccination. In contrast, protection from HIV-1 acquisition in the modestly successful RV144 vaccine trial (31% efficacy) was not associated with bNAbs, but correlated with nonneutralizing antibodies against the variable 1 and 2 (V1V2) regions of Env [11,12]. Reduced risk of infection among vaccinees also correlated with anti-Env antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) in the

presence of low plasma titers of anti-Env IgA. These immune correlates have spurred renewed interest in fragment crystallizable (Fc)-mediated nonneutralizing functions of HIV-1-specific antibodies.

HIV-1-specific ADCC involves the binding of the antigen-binding fragment (Fab) of antibodies to Env expressed on infected cells and the subsequent cross-linking of Fc gamma receptors (FcγR) on innate effector cells including natural killer (NK)

^aDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, ^bMelbourne Sexual Health Centre and Department of Infectious Diseases, Central Clinical School, Monash University and ^cARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, VIC, Australia

Correspondence to Stephen J. Kent, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne 3000 VIC Australia.

Tel: +61 3 83449939; e-mail: skent@unimelb.edu.au

Curr Opin HIV AIDS 2017, 12:000–000

DOI:10.1097/COH.0000000000000439

KEY POINTS

- Broadly neutralizing and nonneutralizing monoclonal antibodies can mediate ADCC *in vitro* against cells infected with lab-adapted and primary isolates of HIV-1.
- Fc effector functions may contribute to the protective efficacy of broadly neutralizing antibodies against cell-free and cell-associated HIV-1 challenge in murine and nonhuman primate models
- HIV-1 can evade ADCC by downregulating the expression of Env glycoproteins on the surface of infected cells and by concealing CD4-induced epitopes on Env that are highly targeted by antibodies induced in HIV-1 infection.

cells and monocytes [13,14]. The crosslinking of FcγRs activates these innate effector cells to secrete a series of cytokines and chemokines, and induces degranulation of cytotoxic granules containing perforin and granzyme B.

This review discusses recent advances in anti-HIV-1 ADCC research and highlights ADCC research presented at the 9th IAS Conference on HIV Science (IAS 2017). We present a particular focus on ADCC mediated by Env-specific monoclonal antibodies (mAbs) *in vitro* and *in vivo*, discuss the curative potential of HIV-1-specific ADCC antibodies and the mechanisms of resistance to ADCC.

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY MEDIATED BY ENV-SPECIFIC MONOCLONAL ANTIBODIES *IN VITRO*

Over the years, an array of Env-specific mAbs have been isolated from HIV-1-infected patients [15]. These mAbs can generally be classified into neutralizing antibodies, which can bind to Env on HIV-1 virions and block infection, or nonneutralizing antibodies. Although the neutralization capacity of mAbs has been very well characterized with the standardized TZM-B1 neutralization assay against a large panel of HIV-1 strains, the ADCC potential of mAbs has been less well defined with the lack of a standardized ADCC assay across different research groups. It is still not known which ADCC assays are the most physiologically relevant or the most predictive of *in vivo* efficacy. Assays to measure ADCC activity vary greatly depending on a multitude of factors including the type of target cell used, conformation of Env, isotype subclass of the antibody and the type of effector cell used [13,16]. In particular, the conformation of Env, whether in its native

closed trimeric state or open CD4-bound conformation with CD4i epitopes exposed, will govern whether many mAbs can bind and mediate ADCC.

It is important to note that neutralization and Fc-mediated effector functions are not mutually exclusive and can in fact overlap substantially. Von Bredow *et al.* [17] compared the ADCC and neutralization activities of a large panel of neutralizing and nonneutralizing mAbs directed against a range of different epitopes on HIV-1 Env. Although ADCC and neutralization were largely correlated, some mAbs were able to mediate ADCC in the absence of neutralization activity, and vice versa. ADCC in the absence of neutralization was observed particularly against cells infected with lab-adapted viruses, where certain Env epitopes that are absent on the HIV-1 virion were exposed on the surface of infected cells.

Another study characterized the *in-vitro* ADCC activity of a broad range of bNAbs against cells infected with the lab-adapted NLAD8 and NL4.3 strains and several primary transmitted/founder (T/F) HIV-1 isolates [18^{*}]. The ADCC activity of these bNAbs correlated positively with binding to infected cells and neutralization. The authors reported that the binding of bNAbs to cells infected with the primary T/F isolates was much lower compared with cells infected with the lab-adapted HIV-1 strains. The combination of five bNAbs targeting multiple different epitopes on Env improved binding and resulted in ADCC against cells infected with most of the T/F isolates, albeit at a lower level compared with cells infected with the lab-adapted strains. In line with a previous study showing that a combination of bNAbs improved neutralization potency and breadth against T/F viruses [19], these results suggest that bNAb combinations targeting different epitopes can enhance the potency and breadth of the ADCC response as well. In a similar study, Bruel *et al.* [20] compared the ADCC activity of nine nonneutralizing mAbs and five potent bNAbs. The authors found that although the nonneutralizing mAbs could mediate ADCC against cells infected with lab-adapted HIV-1 strains, they inefficiently recognized and killed cells infected with primary T/F isolates and *ex-vivo* reactivated cells from HIV-1⁺ patients. On the contrary, Mayr *et al.* [21] examined a different panel of nonneutralizing mAbs directed against the V1V2 region of Env and demonstrated that these nonneutralizing V1V2 mAbs mediated greater ADCC against cells infected with the primary HIV-1 isolate SF162 compared with several bNAbs tested. These V1V2 nonneutralizing mAbs shared similar specificities with antibodies that correlated with lowered risk of infection in the RV144 trial. The authors further demonstrated that the V1V2 mAbs could mediate ADCC against cells infected with

several subtype B and C primary HIV-1 isolates and two subtype B T/F isolates.

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY MEDIATED BY ENV-SPECIFIC MONOCLONAL ANTIBODIES *IN VIVO*

Although ADCC activity can be relatively easily determined *in vitro*, the protective efficacy of ADCC is much more complicated to determine *in vivo*, where it might be difficult to separate Fc-dependent effects from Fab-dependent neutralizing functions. A seminal study published in 2007 demonstrated that Fc γ R engagement was important in bNAb-mediated protection against mucosal SHIV challenge in macaques [4]. The passive transfer of the LALA variant of b12, with mutations that abrogate Fc γ R-binding, resulted in significantly reduced protection against SHIV challenge compared with the wildtype b12 antibody. A further study using a more physiological low dose repeated SHIV challenge recapitulated these results and showed that b12-treated macaques remained protected from SHIV infection after nearly twice as many challenges compared with macaques treated with the LALA variant [22]. Parsons *et al.* [23^{*}] recently showed that the bNAb PGT121 was partially protective against cell-associated SHIV challenge in macaques. Cell-associated virus may be a significant mechanism of virus transmission [24,25] and ADCC effector functions may be important in preventing infection by this route (Fig. 1). Although Parsons *et al.* did not formally show that Fc effector functions contributed to this partial efficacy *in vivo*, *in vitro* experiments demonstrated that PGT121 could engage macaque Fc γ Rs and activate macaque NK cells. Macaque effector peripheral blood mononuclear cells (PBMCs) were also able to mediate ADCC against HIV-1-infected target cells using PGT121. One of us (Kent) presented this work at IAS 2017 and noted the implications for the ongoing antibody-mediated prevention (AMP) efficacy trials (NCT02568215 and NCT02716675) [26]. It is possible that efficacy in these trials may be reduced if cell-associated transmissions of HIV-1 can evade the VRC01 bNAb infusions, as it has been demonstrated that VRC01 has reduced efficacy against cell-to-cell transmission of HIV-1 *in vitro* [25,27]. Further macaque experiments are planned to determine whether Fc effector functions can contribute to protection against cell-associated SHIV challenge by using the non-Fc γ R-binding LALA variant of PGT121.

The importance of Fc γ R-binding for bNAb-mediated protection *in vivo* has also been demonstrated in several studies utilizing mouse models of HIV-1




FIGURE 1. Mechanisms of protection mediated by broadly neutralizing antibodies. (a) bNAbs can prevent HIV-1 infection by directly neutralizing cell-free virions. (b) Cell-to-cell transmission of HIV-1 is a significant mode of viral transmission and is relatively hidden from some bNAbs [25]. bNAbs will need to access the virological synapse and neutralize virions to block cell-mediated spread of HIV-1. (c) ADCC-competent bNAbs might play a role in preventing cell-associated spread of HIV-1 by targeting Env on the surface of infected cells and killing the infected cells by engaging effector cells including NK cells. ADCC, antibody-dependent cellular cytotoxicity; bNAbs, broadly neutralizing antibodies; NK, natural killer.

infection. Bournazos *et al.* [28] first showed that mice given the bNAb 10-1074 with the GASDALIE mutation, which improves affinity towards activating Fc γ Rs, had lower viral loads following adoptive transfer of HIV-1-infected CD4⁺ T cells compared with mice administered bNAbs with the GRLR mutation that abrogates Fc γ R-binding. In a similar study, ART-treated mice were administered with the bNAbs 3BNC117 and 10-1074 or the GRLR variants before

being adoptively transferred with HIV-1-infected cells [29^{***}]. There was a significantly lower percentage of HIV-1 Gag⁺ infected cells in the mice treated with wildtype bNAb compared with mice receiving the GRLR variants. The authors provided further evidence that the bNAb-mediated depletion of infected cells *in vivo* was Fc γ R-dependent as this clearance was diminished when the mice were treated with Fc γ R-blocking antibodies. In a postexposure prophylaxis model, where humanized mice were treated with a triple mix of bNAbs 4 days after challenge with HIV-1, only 1 of 21 mice exhibited rebound in viremia in the group receiving wildtype bNAbs compared with 9 of 15 mice in the group receiving bNAbs with the GRLR mutation [30].

A recent murine study examined the *in vivo* ADCC activity of a broadly neutralizing CD4-antibody fusion protein that constituted of a subunit of the CD4 protein and an antibody domain specific for the gp120 coreceptor-binding site on each arm [31]. This fusion protein had improved binding to the neonatal FcR for increased half-life *in vivo* and a defucosylated IgG₁ Fc domain for increased affinity toward Fc γ RIIIa. This fusion protein eliminated more than 80% of HIV-1-infected cells *in vivo* in an infected humanized mouse model. Further experiments demonstrated that this *in vivo* ADCC was NK cell-dependent as clearance of infected cells was substantially diminished following depletion of CD56⁺ NK cells.

The modest level of protection observed in the RV144 trial correlated with nonneutralizing antibodies against the V1V2 region of Env [12]; however, more definitive evidence of the protection conferred by these nonneutralizing antibodies *in vivo* is needed. Passive transfer of nonneutralizing mAbs has previously showed minimal or no protective efficacy against mucosal SHIV challenge and there has been limited direct evidence that these nonneutralizing antibodies can exert substantial immune pressure on HIV-1 *in vivo* [32–34]. A recent study by Horwitz *et al.* [35^{***}] showed that passive transfer of nonneutralizing antibodies could select for resistant viruses *in vivo* in an Fc-dependent manner. The nonneutralizing mAb 246D, directed against the gp41 stump, was able to modestly clear adoptively transferred HIV-1_{YU2}-infected cells compared with a control mAb. Although unable to suppress viremia in humanized mice with established HIV-1_{YU2} infection, wildtype 246D was able to select for viruses with a recurring mutation that limited exposure of its gp41 epitope compared with the 246D-GRLR variant, which had abrogated Fc γ R-binding. Similar escape mutations were observed when a primary transmitted/founder isolate of HIV-1 was used. These results provide more

conclusive evidence that nonneutralizing antibodies can select for viral escape mutants in an Fc-dependent manner.

HIV-1 CURE: POTENTIAL ROLE FOR ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ANTIBODIES

Current HIV-1 treatment regimens are not curative as they do not eliminate the reservoir of long-lived latently infected cells that harbor quiescent but replication-competent proviruses [36]. Most HIV-1 cure research has focused on the ‘shock and kill’ cure approach that aims to reactivate HIV-1 expression in latently infected cells and subsequently kill the reactivated cells through immune-mediated mechanisms [37]. Several candidate latency-reversing agents (LRA) have been examined *in vivo* but none of them have reduced the size of the latent reservoir [38–40]. This suggests that additional immune interventions might need to be harnessed to help eliminate reactivated cells. An issue in utilizing autologous ADCC responses is that HIV-1-specific ADCC antibodies decline in patients on long-term ART [41,42]. A recent study also showed that treatment with panobinostat, a candidate LRA, did not provide sufficient antigenic stimulus to boost autologous anti-HIV-1 ADCC antibodies [43]. If autologous ADCC responses are insufficient to eliminate reactivated cells, the passive transfer of ADCC-competent bNAbs in conjunction with latency reversal might be a more promising approach.

Indeed, ex-vivo reactivated cells from ART-suppressed HIV-1-infected patients can serve as targets for ADCC mediated by bNAbs. Bruel *et al.* [18^{*,20}] show that a mixture of bNAbs or several potent bNAbs individually could mediate ADCC against reactivated HIV-1-infected CD4⁺ T cells derived from HIV-1⁺ donors. Although these results seem promising, the patient-derived CD4⁺ T cells had to be stimulated with phytohemagglutinin and cultured for 7–12 days before HIV-1 Gag expression could be detected. Such high levels of reactivation may not be attainable *in vivo* with the current generation of LRAs.

The only demonstration of *in vivo* efficacy for the shock and kill approach using bNAbs has been in an HIV-1-infected humanized mouse model. In the study by Halper-Stromberg *et al.* [30], there was a decreased proportion of mice exhibiting viral rebound in the group treated with a combination of bNAbs (3BNC117, 10-1074 and PG16) and a combination of LRAs (vorinostat, I-BET151 and anti-CTLA4), compared with mice receiving bNAbs alone or mice receiving bNAbs and a single LRA. These results suggest that a combination of bNAbs

and sufficient reactivation of viral expression might be able to reduce the size of the latent reservoir. Further studies in nonhuman primate models or human clinical trials will need to be conducted to determine if this approach is feasible with a larger and more genetically diverse latent reservoir. Sufficient Env expression on the surface of reactivated cells will likely be necessary for bNAbs to target and eliminate the reactivated cells via ADCC.

POTENTIAL MECHANISMS OF RESISTANCE TO ANTI-HIV-1 ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY

Evans [44] summarized the various mechanisms of HIV-1 resistance to ADCC at IAS 2017. An important determinant of ADCC against HIV-1-infected cells is the antigen density of Env on the surface of infected cells for antibody-binding [45]. The expression of Env on the surface of HIV-1-infected cells is tightly regulated for the optimal level of Env incorporation into budding virions and for subsequent HIV-1 infectivity. The gp41 glycoprotein within Env contains a membrane-proximal endocytosis motif in its cytoplasmic tail that regulates the surface expression of Env prior to virus assembly [46]. Von Bredow *et al.* [47] showed that amino acid substitutions within this endocytosis motif results in accumulation of Env on the surface of the infected cell, increasing binding of Env-specific antibodies and directly increasing susceptibility to ADCC. In addition, HIV-1 Vpu can protect infected cells from ADCC by antagonizing tetherin, an interferon-inducible restriction factor that tethers budding virions to the surface of the infected cell. By blocking tetherin, Vpu prevents the accumulation of virions on the surface, thereby reducing the density of Env glycoproteins available for antibody-binding and ADCC [48,49].

Apart from directly reducing Env antigen density on the surface of infected cells, HIV-1 is able to limit the exposure of epitopes on Env for antibody-binding. Several studies now show that CD4-down-regulation by Vpu and Nef prevents the interaction of Env and CD4 on the surface of infected cells, thereby reducing exposure of the CD4i inner domain epitopes that are highly targeted by ADCC antibodies present in HIV-1⁺ sera [50,51]. Alshafi *et al.* [52,53] demonstrated that Nef isolates from HIV-1 elite controllers more poorly downregulate CD4 from the surface of infected cells compared with HIV-1 progressors, resulting in increased exposure of CD4i epitopes and increased susceptibility to ADCC mediated by HIV-1⁺ sera. The authors suggested that this enhanced ADCC against the viral isolates with impaired Nef could be a contributing

factor to the prolonged suppression of viremia in the absence of ART for these elite controllers.

A potential way to overcome the concealment of CD4i ADCC epitopes on Env is to utilize small molecule CD4 mimetic compounds (CD4mc) that engage Env in a similar manner to soluble CD4 and trigger conformational changes that reveal the inner domain CD4i epitopes [54]. These CD4mc have been shown to enhance binding of antibodies within HIV-1⁺ sera, breast milk and cervicovaginal fluids to infected cells and enhance ADCC against ex-vivo-amplified primary CD4⁺ T cells using autologous effector cells and serum antibodies [55,56].

BREADTH OF ANTIBODY RECOGNITION AND FRAGMENT CRYSTALLIZABLE EFFECTOR FUNCTIONS AS IMPORTANT DETERMINANTS OF PROTECTIVE IMMUNITY

A clear limitation of some bNAbs in macaque passive transfer studies is whenever the bNAbs are not sufficiently broad to protect against the HIV-1 strain employed for challenge [57^{*}]. This has been mirrored in humans with passive administration of a bNAb therapeutically, where preexisting resistant viruses reduced the therapeutic efficacy of the bNAb VRC01 [58]. This issue of breadth of coverage will presumably also translate to the efficacy of antibodies that mediate nonneutralizing Fc effector functions but direct evidence is lacking. Using novel assays of Fc receptor binding, McLean *et al.* [59^{**}] recently found Fc γ R-binding antibodies from RV144 vaccinees had fairly modest recognition of a diverse panel of Env proteins. In contrast, HIV-1 infected patients who naturally control HIV-1 have been shown to have broad recognition of HIV-1 Env proteins by antibodies capable of engaging Fc γ receptors [60].

Antibodies can initiate a wide array of Fc-mediated functions through diverse innate effector cells. This subject, termed 'systems serology' was reviewed in the context of HIV-1 by Alter [61] at IAS 2017. For the RV144 trial, both Yates *et al.* [62] and Chung *et al.* [63] showed HIV-1-specific IgG3 was a key driver of Fc-mediated functions. Chung *et al.* [63] subsequently identified broad patterns in Fc-functional antibodies that correlated with protection from infection and the broad principle of this work was also applicable to antibodies against mycobacterium tuberculosis [64].

CONCLUSION

An increasing number of studies are dissecting the contributions of Fc-mediated effector functions to

antibody-mediated immunity against HIV-1. New methods developed to systematically dissect and analyze the humoral response towards HIV-1 may reveal new insights into the roles functional antibodies may play in vaccine-mediated protection against HIV-1 [59^{***},63,65,66]. Both Fab and Fc arms of anti-HIV-1 antibodies will likely have important and complementary roles to play in HIV-1 prevention, therapeutic and curative strategies.

Acknowledgements

We thank Dr. Matthew S. Parsons for reviewing the manuscript and providing helpful feedback.

Financial support and sponsorship

This work was supported by the Australian National Health and Medical Research Council.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. *Annu Rev Immunol* 2016; 34:635–659.
2. Pegu A, Hessel AJ, Mascola JR, Haigwood NL. Use of broadly neutralizing antibodies for HIV-1 prevention. *Immunol Rev* 2017; 275:296–312.
3. Veazey RS, Shattock RJ, Pope M, *et al.* Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. *Nat Med* 2003; 9:343–346.
4. Hessel AJ, Hangartner L, Hunter M, *et al.* Fc receptor but not complement binding is important in antibody protection against HIV. *Nature* 2007; 449:101–104.
5. Moldt B, Rakasz EG, Schultz N, *et al.* Highly potent HIV-specific antibody neutralization *in vitro* translates into effective protection against mucosal SHIV challenge *in vivo*. *Proc Natl Acad Sci U S A* 2012; 109:18921–18925.
6. Moog C, Dereuddre-Bosquet N, Teillaud JL, *et al.* Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. *Mucosal Immunol* 2014; 7:46–56.
7. Pegu A, Yang ZY, Boyington JC, *et al.* Neutralizing antibodies to HIV-1 envelope protect more effectively *in vivo* than those to the CD4 receptor. *Sci Transl Med* 2014; 6:243ra288.
8. Shingai M, Donau OK, Plishka RJ, *et al.* Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. *J Exp Med* 2014; 211:2061–2074.
9. Veselinovic M, Neff CP, Mulder LR, Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. *Virology* 2012; 432:505–510.
10. Deruaz M, Moldt B, Le KM, *et al.* Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: a model for studying the efficacy of neutralizing antibodies *in vivo*. *J Infect Dis* 2016; 214:612–616.
11. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, *et al.* Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med* 2009; 361:2209–2220.
12. Haynes BF, Gilbert PB, McElrath MJ, *et al.* Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med* 2012; 366:1275–1286.
13. Kramski M, Parsons MS, Stratov I, Kent SJ. HIV-specific antibody immunity mediated through NK cells and monocytes. *Curr HIV Res* 2013; 11: 388–406.
14. Smalls-Mantey A, Connors M, Sattentau QJ. Comparative efficiency of HIV-1 infected T cell killing by NK cells, monocytes and neutrophils. *PLoS One* 2013; 8:e74858.
15. McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. *Immunol Rev* 2017; 275:11–20.
16. Wines BD, Billings H, McLean MR, *et al.* Antibody functional assays as measures of Fc receptor-mediated immunity to HIV - new technologies and their impact on the HIV vaccine field. *Curr HIV Res* 2017; 15:202–215.
17. von Bredow B, Arias JF, Heyer LN, *et al.* Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies. *J Virol* 2016; 90:6127–6139.
18. Bruel T, Guivel-Benhassine F, Amraoui S, *et al.* Elimination of HIV-1-infected cells by broadly neutralizing antibodies. *Nat Commun* 2016; 7:10844.
19. This study assessed the ADCC capacities of several bNAbs *in vitro* and also showed that a cocktail of bNAbs can eliminate ex-vivo reactivated HIV-1-infected CD4⁺ T cells from ART-suppressed HIV-1-infected patients.
19. Kong R, Louder MK, Wagh K, *et al.* Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. *J Virol* 2015; 89:2659–2671.
20. Bruel T, Guivel-Benhassine F, Lorin V, *et al.* Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies. *J Virol* 2017; 91:e02440-16.
21. Mayr LM, Decoville T, Schmidt S, *et al.* Nonneutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity. *Sci Rep* 2017; 7:12655.
22. Hessel AJ, Poignard P, Hunter M, *et al.* Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. *Nat Med* 2009; 15:951–954.
23. Parsons MS, Lloyd SB, Lee WS, *et al.* Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. *Sci Transl Med* 2017; 9; eaaf1483.
24. This study demonstrated that a bNAb was not fully protective against cell-associated SHIV challenge in macaques.
24. Anderson DJ, Politch JA, Nadolski AM, *et al.* Targeting Trojan Horse leukocytes for HIV prevention. *AIDS* 2010; 24:163–187.
25. Malbec M, Porrot F, Rua R, *et al.* Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. *J Exp Med* 2013; 210:2813–2821.
26. Kent SJ. bNAbs and partial control of cell-associated SHIV infection. 9th IAS Conference on HIV Science (IAS 2017); 23–26 July, 2017; Paris, France. Abstract TUSY0204.
27. Abela IA, Berlinger L, Schanz M, *et al.* Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. *PLoS Pathog* 2012; 8:e1002634.
28. Bournazos S, Klein F, Pietzsch J, *et al.* Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for *in vivo* activity. *Cell* 2014; 158:1243–1253.
29. Lu CL, Murakowski DK, Bournazos S, *et al.* Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 *in vivo*. *Science* 2016; 352:1001–1004.
30. This study provided evidence that bNAbs can clear HIV-1-infected cells *in vivo* in an Fc- and Fcy receptor-dependent manner
30. Halper-Stromberg A, Lu CL, Klein F, *et al.* Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. *Cell* 2014; 158:989–999.
31. Bardhi A, Wu Y, Chen W, *et al.* Potent *in vivo* NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein. *J Virol* 2017; 91:e00937-17.
32. Burton DR, Hessel AJ, Keele BF, *et al.* Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. *Proc Natl Acad Sci U S A* 2011; 108:11181–11186.
33. Chung AW, Isitman G, Navis M, *et al.* Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. *Proc Natl Acad Sci U S A* 2011; 108:7505–7510.
34. Santra S, Tomaras GD, Warrier R, *et al.* Human nonneutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. *PLoS Pathog* 2015; 11: e1005042.
35. Horwitz JA, Bar-On Y, Lu CL, *et al.* Nonneutralizing antibodies alter the course of HIV-1 infection *in vivo*. *Cell* 2017; 170:637–648.e10.
36. This study showed ADCC-mediated nonneutralizing antibodies can select for immune escape mutations in HIV-1-infected humanized mice in an Fc-dependent manner.
36. Siliciano JD, Kajdas J, Finzi D, *et al.* Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4⁺ T cells. *Nat Med* 2003; 9:727–728.
37. Deeks SG. HIV: shock and kill. *Nature* 2012; 487:439–440.
38. Elliott JH, Wightman F, Solomon A, *et al.* Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. *PLoS Pathog* 2014; 10:e1004473.
39. Rasmussen TA, Tolstrup M, Brinkmann CR, *et al.* Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. *Lancet HIV* 2014; 1:e13–e21.
40. Sogaard OS, Graversen ME, Leth S, *et al.* The deipeptide romidepsin reverses HIV-1 latency *in vivo*. *PLoS Pathog* 2015; 11:e1005142.
41. Madhavi V, Ana-Sosa-Batiz FE, Jegaskanda S, *et al.* Antibody-dependent effector functions against HIV decline in subjects on antiretroviral therapy. *J Infect Dis* 2014; 211:529–538.

42. Madhavi V, Kulkarni A, Shete A, *et al.* Effect of combination antiretroviral therapy on HIV-1-specific antibody-dependent cellular cytotoxicity responses in subtype B- and subtype C-infected cohorts. *J Acquir Immune Defic Syndr* 2017; 75:345–353.
43. Lee WS, Kristensen AB, Rasmussen TA, *et al.* Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption. *J Virol* 2017; 91:e00603-17.
44. Evans DT. Mechanisms of HIV-1 resistance to ADCC. 9th IAS Conference on HIV Science (IAS 2017); July 23–26, 2017; Paris, France. Abstract WESY0505.
45. Smalls-Mantey A, Doria-Rose N, Klein R, *et al.* Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4⁺ T cells is directly associated with the magnitude of surface IgG binding. *J Virol* 2012; 86:8672–8680.
46. Boge M, Wyss S, Bonifacino JS, Thali M. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. *J Biol Chem* 1998; 273:15773–15778.
47. von Bredow B, Arias JF, Heyer LN, *et al.* Envelope glycoprotein internalization protects human and simian immunodeficiency virus-infected cells from antibody-dependent cell-mediated cytotoxicity. *J Virol* 2015; 89:10648–10655.
48. Arias JF, Heyer LN, von Bredow B, *et al.* Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. *Proc Natl Acad Sci U S A* 2014; 111:6425–6430.
49. Alvarez RA, Hamlin RE, Monroe A, *et al.* HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. *J Virol* 2014; 88:6031–6046.
50. Veillette M, Desormeaux A, Medjahed H, *et al.* Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. *J Virol* 2014; 88:2633–2644.
51. Veillette M, Coutu M, Richard J, *et al.* The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. *J Virol* 2015; 89:545–551.
52. Alshahafi N, Ding S, Richard J, *et al.* Nef proteins from HIV-1 elite controllers are inefficient at preventing antibody-dependent cellular cytotoxicity. *J Virol* 2015; 90:2993–3002.
53. Alshahafi N, Richard J, Prevost J, *et al.* Impaired downregulation of NKG2D ligands by Nef proteins from elite controllers sensitizes HIV-1-infected cells to antibody-dependent cellular cytotoxicity. *J Virol* 2017; 91:e00109-17.
54. Schon A, Madani N, Klein JC, *et al.* Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. *Biochemistry* 2006; 45:10973–10980.
55. Richard J, Veillette M, Brassard N, *et al.* CD4 mimetics sensitize HIV-1-infected cells to ADCC. *Proc Natl Acad Sci U S A* 2015; 112:E2687–E2694.
56. Lee WS, Richard J, Lichtfuss M, *et al.* Antibody-dependent cellular cytotoxicity against reactivated HIV-1-infected cells. *J Virol* 2016; 90:2021–2030.
57. Julg B, Liu PT, Wagh K, *et al.* Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. *Sci Transl Med* 2017; 9:eaa04235. ■ This study illustrates the importance of breadth of bNAbs in the protection of macaques from SHIV challenge.
58. Lynch RM, Boritz E, Coates EE, *et al.* Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. *Sci Transl Med* 2015; 7:319ra206.
59. McLean MR, Madhavi V, Wines BD, *et al.* Dimeric Fcγ receptor enzyme-linked immunosorbent assay to study HIV-specific antibodies: a new look into breadth of Fcγ receptor antibodies induced by the RV144 Vaccine Trial. *J Immunol* 2017; 199:816–826. ■■ This publication showed that the RV144 Vaccine Trial induced ADCC antibodies with only modest breadth against HIV-1 Env antigens.
60. Madhavi V, Wren LH, Center RJ, *et al.* Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. *AIDS* 2014; 28:1859–1870.
61. Alter G. Polyfunctional antibodies in HIV infection and vaccination. 9th IAS Conference on HIV Science (IAS 2017); 23–26 July 2017; Paris, France. Abstract WESY0502.
62. Yates NL, Liao HX, Fong Y, *et al.* Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. *Sci Transl Med* 2014; 6:228ra239.
63. Chung AW, Kumar MP, Arnold KB, *et al.* Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. *Cell* 2015; 163:988–998.
64. Lu LL, Chung AW, Rosebrock TR, *et al.* A functional role for antibodies in tuberculosis. *Cell* 2016; 167:433.e14–443.e14.
65. Ackerman ME, Barouch DH, Alter G. Systems serology for evaluation of HIV vaccine trials. *Immunol Rev* 2017; 275:262–270.
66. Madhavi V, Wines BD, Amin J, *et al.* HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV. *J Virol* 2017; 91:e00700-17.